Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 8 (2019)

Level of copeptin and NT-proBNP in patients with decompensated heart failure in the post-infarction period under the influence of treatment

Author(s):
Kh. Levandovska
Abstract:
Copeptin is a C-terminal fragment of pro-vasopressin and a part of vasopressin precursor - pre-pro-vasopressin. The precursor is cleaved, while copeptin and vasopressin are released in equal equimolar amounts. The advantages of using copeptin include its stability, easy and rapid measurements. Its mean plasma concentration is 4.2 pmol/l. Copeptin is a promising biomarker of diagnosis and clinical course of heart failure and its decompensation.
The aim of the study was to assess the feasibility of using copeptin and NT-proBNP in the patients with decompensated heart failure in the early and late post-infarction periods and to determine changes in their correlation during the rehabilitation process.
Materials and Methods: There were examined 120 patients with Q-QS wave and non-Q wave myocardial infarction, stage II A-B decompensated chronic heart failure according to the classification proposed by Vasylenko V.Kh. and Strazhesko M.D., the New York Heart Association functional class III-IV.
Studygroupswerehomogenous by age, gender, disease severity, duration of the post-infarction period, clinical signs of decompensation, that served as a basis for inclusion of the patients in the study.
All the patients underwent the six-minute walk test in a quiet 30-50-m long hospital corridorin the morning. In all the patients, serum concentration of N-terminal pro-brain natriuretic peptide (pg/mg) was determined using commercial ELISA kit forHumanN-terminal pro-brain natriuretic peptide (Biomedica, Slovakia S.R.O.). The results obtained were statistically processed on the personal computer by means of an advanced analytics software package STATISTICA-7 and a statistical software package “Microsoft-Excel” using the statistical variation analysis. During 2 months of treatment, plasma copeptin levels decreased in all the study groups.
Results and Discussion: When studying a dynamic of changes in blood level of N-terminal pro-brain natriuretic peptide, there was observed its significant reduction in all the groups after treatment. The combined use of succinic acid and arginine preparations when treating the patients with Q wave and non-Q wave myocardial infarction and decompensated heart failure allowed us to reduce blood levels of N-terminal pro-brain natriuretic peptide by 41.03% and 41.61% 2 months after the beginning of treatment. The combined use of succinic acid and arginine preparations in combination therapy for decompensated heart failure allowed us to reduce blood levels of N-terminal pro-brain natriuretic peptide under conditions of graded exercises. Thus, during treatment of the patients of all the study groups, there was observed a gradual reduction in the concentration of N-terminal pro-brain natriuretic peptide in the blood both at rest and during graded exercises.
Conclusions: Copeptin and N-terminal pro-brain natriuretic peptide levels can be used both for the prediction of heart failure in the post-infarction period and quality assessment of treatment performed.
Pages: 220-227  |  546 Views  46 Downloads


The Pharma Innovation Journal
How to cite this article:
Kh. Levandovska. Level of copeptin and NT-proBNP in patients with decompensated heart failure in the post-infarction period under the influence of treatment. Pharma Innovation 2019;8(8):220-227.

Call for book chapter